CytomX Therapeutics Statistics
Total Valuation
CTMX has a market cap or net worth of $171.72 million. The enterprise value is $99.99 million.
Important Dates
The last earnings date was Monday, May 12, 2025, before market open.
| Earnings Date | May 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CTMX has 80.62 million shares outstanding. The number of shares has increased by 10.23% in one year.
| Current Share Class | 80.62M |
| Shares Outstanding | 80.62M |
| Shares Change (YoY) | +10.23% |
| Shares Change (QoQ) | +1.64% |
| Owned by Insiders (%) | 0.92% |
| Owned by Institutions (%) | 51.69% |
| Float | 74.65M |
Valuation Ratios
The trailing PE ratio is 4.39.
| PE Ratio | 4.39 |
| Forward PE | n/a |
| PS Ratio | 1.24 |
| Forward PS | 1.90 |
| PB Ratio | 7.41 |
| P/TBV Ratio | 7.29 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | 2.40 |
| EV / Sales | 0.68 |
| EV / EBITDA | 2.66 |
| EV / EBIT | 2.78 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.73, with a Debt / Equity ratio of 0.33.
| Current Ratio | 1.73 |
| Quick Ratio | 1.63 |
| Debt / Equity | 0.33 |
| Debt / EBITDA | 0.20 |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | 15.87% |
| Return on Invested Capital (ROIC) | 312.36% |
| Return on Capital Employed (ROCE) | 74.46% |
| Revenue Per Employee | $1.22M |
| Profits Per Employee | $343,826 |
| Employee Count | 121 |
| Asset Turnover | 1.04 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, CTMX has paid $237,000 in taxes.
| Income Tax | 237,000 |
| Effective Tax Rate | 0.57% |
Stock Price Statistics
The stock price has increased by +7.58% in the last 52 weeks. The beta is 1.11, so CTMX's price volatility has been higher than the market average.
| Beta (5Y) | 1.11 |
| 52-Week Price Change | +7.58% |
| 50-Day Moving Average | 0.70 |
| 200-Day Moving Average | 0.97 |
| Relative Strength Index (RSI) | 85.66 |
| Average Volume (20 Days) | 8,065,731 |
Short Selling Information
The latest short interest is 9.74 million, so 12.09% of the outstanding shares have been sold short.
| Short Interest | 9.74M |
| Short Previous Month | 9.57M |
| Short % of Shares Out | 12.09% |
| Short % of Float | 13.05% |
| Short Ratio (days to cover) | 8.13 |
Income Statement
In the last 12 months, CTMX had revenue of $147.56 million and earned $41.60 million in profits. Earnings per share was $0.49.
| Revenue | 147.56M |
| Gross Profit | 147.56M |
| Operating Income | 35.96M |
| Pretax Income | 15.08M |
| Net Income | 41.60M |
| EBITDA | 37.65M |
| EBIT | 35.96M |
| Earnings Per Share (EPS) | $0.49 |
Full Income StatementBalance Sheet
The company has $79.89 million in cash and $8.15 million in debt, giving a net cash position of $71.74 million or $0.89 per share.
| Cash & Cash Equivalents | 79.89M |
| Total Debt | 8.15M |
| Net Cash | 71.74M |
| Net Cash Per Share | $0.89 |
| Equity (Book Value) | 25.05M |
| Book Value Per Share | 0.29 |
| Working Capital | 36.43M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$81.23 million and capital expenditures -$314,000, giving a free cash flow of -$81.54 million.
| Operating Cash Flow | -81.23M |
| Capital Expenditures | -314,000 |
| Free Cash Flow | -81.54M |
| FCF Per Share | -$1.01 |
Full Cash Flow StatementMargins
Gross margin is 100.00%, with operating and profit margins of 24.37% and 28.19%.
| Gross Margin | 100.00% |
| Operating Margin | 24.37% |
| Pretax Margin | 28.36% |
| Profit Margin | 28.19% |
| EBITDA Margin | 25.51% |
| EBIT Margin | 24.37% |
| FCF Margin | n/a |